Statement Of Cash Flows [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166306

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations	—	11,253 EUR	—	4,571 EUR	—
Income taxes paid (refund), classified as operating activities	—	3,000 EUR	—	1,000 EUR	—
Cash flows from (used in) operating activities	—	11,250 EUR	—	4,570 EUR	—
Cash flows from (used in) investing activities [abstract]
Other cash payments to acquire interests in joint ventures, classified as investing activities	—	1,270 EUR	—	- EUR	—
Purchase of property, plant and equipment, classified as investing activities	—	107,000 EUR	—	- EUR	—
Proceeds from sales of intangible assets, classified as investing activities	—	219,000 EUR	—	—	—
Purchase of intangible assets, classified as investing activities	—	954,000 EUR	—	623,000 EUR	—
Purchase of other long-term assets, classified as investing activities	—	21,000 EUR	—	10,000 EUR	—
Cash advances and loans made to other parties, classified as investing activities	—	1,157 EUR	—	—	—
Cash receipts from repayment of advances and loans made to other parties, classified as investing activities	—	216,000 EUR	—	—	—
Other inflows (outflows) of cash, classified as investing activities	—	—	—	- EUR	—
Cash flows from (used in) investing activities	—	3,075 EUR	—	633,000 EUR	—
Cash flows from (used in) financing activities [abstract]
Repayments of borrowings, classified as financing activities	—	62,000 EUR	—	51,000 EUR	—
Cash flows from (used in) financing activities	—	62,000 EUR	—	69,397 EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	14,387 EUR	—	64,194 EUR	—
Cash and cash equivalents	50,012 EUR	—	64,399 EUR	—	205,000 EUR